Melasma is a frequent relapsing pigmentary disorder that significantly impacts quality of life, and no curative treatment is yet available.

Photoprotection against UVB, UVA, and blue–violet visible light (e.g., broad-spectrum tinted sunscreen) is essential for successful treatment, improving pigmentation, preventing relapse, and preventing disease in high-risk individuals.

Topical therapies leading to tyrosinase inhibition are the mainstay of treatment; hydroquinone and triple combination cream are the reference drugs.

Oral therapies (e.g., tranexamic acid) and microneedling can be associated with topical therapies to synergistically increase their efficacy.

Superficial peelings and low-fluence (e.g., Q-switched) laser therapy increase melanin removal from the epidermis, accelerating clinical results.